68Ga-satoreotide trizoxetan PET显像最佳剂量的新型判读方法:胃肠胰神经内分泌肿瘤II期临床试验
该随机2×3析因II期研究纳入24例转移性胃肠胰神经内分泌肿瘤患者,采用二分类视觉判读法评估68Ga-satoreotide trizoxetan PET/CT图像质量,比较三种放射性活度范围(40-80、100-140、160-200 MBq)和两个肽质量范围(5-20 μg与30-45 μg)。结果显示40-80 MBq组总图像质量评分(56.3%)低于100-140 MBq组(90.6%)和160-200 MBq组(81.3%),肽质量不影响显像,判读者间变异低。
要点
- 68Ga-satoreotide trizoxetan最佳给药放射性活度为100-200 MBq,肽质量可达50 μg。
- 40-80 MBq组图像质量评分56.3%,低于100-140 MBq组90.6%和160-200 MBq组81.3%。
- 二分类视觉判读法判读者间变异低,仅一次判读出现分歧。
核心结论
- 二分类视觉判读法判读者间变异低,支持68Ga-satoreotide trizoxetan最佳给药放射性活度为100-200 MBq、肽质量可达50 μg。
研究设计与样本
- 随机2×3析因II期临床研究,纳入24例转移性胃肠胰神经内分泌肿瘤患者。
- 患者第1天接受5-20 μg 68Ga-satoreotide trizoxetan,第16-22天接受30-45 μg,每次访视接受三种镓-68放射性活度范围之一(40-80、100-140或160-200 MBq)。
- 每例患者注射后采集两次68Ga-satoreotide trizoxetan PET/CT,由经验丰富的独立盲法判读者采用二分类系统评分(0为非最佳图像质量,1为最佳图像质量)。
主要发现
- 40-80 MBq放射性活度范围组68Ga-satoreotide trizoxetan PET总图像质量评分为56.3%,低于100-140 MBq组(90.6%)和160-200 MBq组(81.3%)。
- 定性和半定量分析均显示肽质量(5-20或30-45 μg)不影响68Ga-satoreotide trizoxetan显像。
- 仅一次判读出现判读者分歧:一名判读者因病灶显影更清晰偏好某图像,另一名判读者因能识别更多病灶偏好另一图像。
关键数值与推荐
- 二分类视觉判读系统:0分为非最佳图像质量,1分为最佳图像质量。
- 每例患者两次扫描中,一次或两次图像可评1分。
- 最佳给药放射性活度为100-200 MBq,肽质量可达50 μg。
临床怎么用
- 临床使用68Ga-satoreotide trizoxetan PET/CT时,建议给药放射性活度选择100-200 MBq、肽质量不超过50 μg以获得最佳图像质量。
- 可采用二分类视觉判读法评估图像质量,判读者间一致性较好。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the optimal peptide mass and radioactivity ranges for 68Ga-satoreotide trizoxetan, using binary visual reading. To that end, 24 patients with metastatic gastroenteropancreatic neuroendocrine tumours received 5-20 µg of 68Ga-satoreotide trizoxetan on day 1 of the study and 30-45 µg on day 16-22, with one of three gallium-68 radioactivity ranges (40-80, 100-140, or 160-200 MBq) per visit. Two 68Ga-satoreotide trizoxetan PET/CT scans were acquired from each patient post-injection, and were scored by experienced independent blinded readers using a binary system (0 for non-optimal image quality and 1 for optimal image quality). For each patient pair of 68Ga-satoreotide trizoxetan scans, one or both images could score 1. RESULTS: Total image quality score for 68Ga-satoreotide trizoxetan PET scans was lower in the 40-80 MBq radioactivity range (56.3%) compared to 100-140 MBq (90.6%) and 160-200 MBq (81.3%). Both qualitative and semi-quantitative analysis showed that peptide mass (5-20 or 30-45 µg) did not influence 68Ga-satoreotide trizoxetan imaging. There was only one reading where readers diverged on scoring; one reader preferred one image because of higher lesion conspicuity, and the other reader preferred the alternative image because of the ability to identify more lesions. CONCLUSIONS: Binary visual reading, which was associated with a low inter-reader variability, has further supported that the optimal administered radioactivity of 68Ga-satoreotide trizoxetan was 100-200 MBq with a peptide mass up to 50 µg. Trial registration ClinicalTrials.gov, NCT03220217. Registered 18 July 2017, https://clinicaltrials.gov/ct2/show/NCT03220217.
引用
- Miller CG, Grønbæk H, Virgolini I, et al. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. EJNMMI Res. 2021. PMID: 34487283. doi:10.1186/s13550-021-00819-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。